RxDoctor Payments Data

Wright Lauten, MD

Retina Specialist · Hattiesburg, MSNPI 1174781231

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 91.7% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $255, more than ten times the $18 reported in 2019.

$524in general payments, 2019–2025

Across 12 payments — averaging $43.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$481
  • Astellas Pharma US Inc$43

What the payments were for

  • Food & beverage$524100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon10$481
Astellas Pharma US Inc2$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$14,886,956
Medicare patients
2,396
Services billed
214,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol237$60,872
Fluorometholone578$50,800
LumiganBimatoprost109$32,186
Prednisolone Acetate404$16,577
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol107$11,075
Timolol Maleate781$7,674
FlarexFluorometholone Acetate44$5,330
Dorzolamide Hcl297$4,790
Brimonidine Tartrate281$4,451
Alphagan PBrimonidine Tartrate15$4,293
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat243$4,010
Difluprednate27$3,760
Latanoprost455$3,642
Lotemax SmLoteprednol Etabonate14$3,363
SimbrinzaBrinzolamide/Brimonidine Tart14$3,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$481$3,13514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →